Biohm and ADM partner on microbiome formulation for women

By Claudia Adrien

- Last updated on GMT

Biohm is unlocking new insights into human health by combining comprehensive bacterial and fungal biological data with cutting-edge computational biology and AI. @ Luis Alvarez / Getty Images
Biohm is unlocking new insights into human health by combining comprehensive bacterial and fungal biological data with cutting-edge computational biology and AI. @ Luis Alvarez / Getty Images
Microbiome company Biohm Technologies has joined forced with nutrition multinational ADM to launch a new data-driven microbiome formulation called Vivifem, formulated for women between the ages of 45 and 65.

A combination of pre-, pro- and postbiotics to address healthy aging, the product was developed by ADM using Biohm Technologies’ Symbiont platform, an ingredient discovery, selection and formulation tool, along with Biohm’s propriety microbiome dataset to identify microbiome shifts in aging women compared to a younger cohort.

The team then created a formula—which includes probiotic blend Mycosha, prebiotic PreforPro and postbiotic ES1—to modulate the microbiome specifically relative to the target organisms identified. According to Biohm, Vivifem is backed by seven published human clinical trials and dozens of pre-clinical studies.

“Healthy aging and women’s health are two categories that remain ripe for opportunity, and gut microbiome balance plays a tremendous role in these areas,” said Kristin Wilhoyte, vice president of B2B marketing at Biohm Technologies. “Our microbiome dataset allows us to create truly targeted solutions for specific groups of consumers and their needs—in this case, women over 40.”

Sam Schatz, CEO of Biohm, said that the company is unlocking new insights into human health by combining comprehensive bacterial and fungal biological data with cutting-edge computational biology and AI.

“This latest formulation is a testament to this approach and there’s much more to come,” he added.

New corporate brand identity

Along with creating its latest product line, Biohm has recently launched a new corporate brand identity. The branding reflects the company’s redefined strategy centered on B2B solutions in the nutraceutical industry.

Biohm was founded in 2016 by Afif Ghannoum and his father, Dr. Mahmoud Ghannoum, a globally recognized microbiome researcher. The company initially focused on direct-to-consumer offerings surrounding its clinically studied and data-driven Biohm FX (now marketed as Mycohsa) probiotic formulation.

Dr. Ghannoum’s research on the complex relationship between fungi and bacteria in the gut, fueled in large part by the company’s at-home gut microbiome testing data, is the foundation for Biohm’s solutions in probiotics, the company said. Biohm Technologies also offers its comprehensive microbiome gut testing kits as a private label solution for brands in the health and wellness space.

“Biohm’s data innovation and resulting probiotic ingredient formulations are well positioned to serve a broader audience through a variety of channels, and that’s been the driving force behind our shift towards amplifying our B2B offerings,” Schatz said.

Related news

Related products

show more

Key Motivations for Supporting Mental Energy

Key Motivations for Supporting Mental Energy

Content provided by Kyowa Hakko (US) | 08-Oct-2024 | White Paper

Kyowa Hakko's newest consumer research report sheds light on key factors that are driving interest in cognitive health and mental energy. Informed...

Related suppliers

Follow us

Products

View more

Webinars